Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3587 |
Name | pancreatic ductal carcinoma |
Definition | A pancreatic carcinoma located_in the pancreatic duct. |
Source | DiseaseOntology.org |
Alt Ids | DOID:10023 |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic ductal carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CBL dec exp | Erlotinib + Gemcitabine | pancreatic ductal carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01621243 | Phase Ib/II | Gemcitabine + Nab-paclitaxel Necuparanib | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Terminated | USA | CAN | 0 |
NCT01821729 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Losartan | Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer | Unknown status | USA | 0 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02558894 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | NLD | ESP | DEU | CAN | 1 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT04177810 | Phase II | Cemiplimab + Plerixafor | Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT06400485 | Phase I | AMT-676 | AMT-676 in Patients With Advanced Solid Tumors | Recruiting | AUS | 1 |